Vanderbilt researchers developed two new compounds to study the TAOK protein family, linked to Alzheimer's disease, potentially revealing new disease mechanisms and treatment strategies.
Scientists have identified a biological tipping point in microglial behavior that may determine whether Alzheimer's pathology leads to dementia, offering new treatment targets.
A new study reveals that cancer-linked mutations found in immune cells may contribute to Alzheimer's disease, suggesting new diagnostic and treatment avenues.
Scientists at ETH Zurich identified a new Alzheimer's trigger and developed an experimental compound that slowed nerve cell loss and extended lifespan in mice.
Scientists have discovered a molecular switch involving the STING protein that drives brain inflammation in Alzheimer's disease, offering a new target for treatments.
Scientists have identified the enzyme IDOL as a potential new target for Alzheimer's treatment, finding that its removal from neurons significantly reduced amyloid plaques and improved brain resilience in lab studies.
A new study reveals that the amino acid arginine can significantly reduce toxic amyloid protein buildup and inflammation in animal models of Alzheimer's disease.
Researchers discovered that boosting a protein called Sox9 helps the brain's astrocytes clear Alzheimer's plaques and preserve cognitive function in mice.
Researchers have studied SuperAgers, individuals over 80 with memory like 50-year-olds, finding unique brain structures and social traits that resist or adapt to Alzheimer's-related changes.
A routine blood test marker, the neutrophil to lymphocyte ratio, may predict a person's risk of developing Alzheimer's disease years before symptoms appear, suggesting immune cells could play a role in the disease's progression.